Blog of Signaling Pathways

Targeting glutamine metabolism with photodynamic immunotherapy for metastatic tumor eradication

52 views | Jul 04 2023

The study presents a novel photodynamic immunostimulant, BVC, that reprograms glutamine metabolism and combines immune checkpoint blockade therapy with photodynamic therapy to enhance immune recognition and prevent immune escape for the eradication of metastatic tumors. [Read the Full Post]

Design, synthesis, and evaluation of PD-1/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold

88 views | Jul 04 2023

Compound D3, a novel small-molecule inhibitor of the PD-1/PD-L1 interaction, demonstrates potent inhibitory activity and immune-enhancing effects, making it a promising candidate for further development in immunotherapy. [Read the Full Post]

Proof of concept nanotechnological approach to in vitro targeting of malignant melanoma for enhanced immune checkpoint inhibition

69 views | Jul 04 2023

The study demonstrates that the delivery of a small molecule inhibitor of the PD-1/PD-L1 pathway using nanodiamond-based nanoparticles enhances immune cell stimulation and promotes stronger interactions between immune cells and melanoma cells, suggesting potential for improved melanoma therapy. [Read the Full Post]

Long non‑coding RNA LINC01960‑201 hinders decidualization of endometrial stromal cell in endometriosis: Relevance to endometrial receptivity

147 views | Jul 03 2023

The study suggests that LINC01960-201 may play a regulatory role in the decidualization of endometrial stromal cells in women with endometriosis during the window of implantation, potentially affecting endometrial receptivity and recurrent abortions. [Read the Full Post]

Targeting transient receptor potential canonical 1 reduces non‑small cell lung cancer chemoresistance and stemness via inhibition of PI3K/AKT signaling

25 views | Jul 03 2023

Targeting TRPC1 in non-small cell lung cancer (NSCLC) could reduce chemoresistance and cancer stemness by suppressing PI3K/Akt signaling, suggesting it as a potential therapeutic approach. [Read the Full Post]

Combined inhibition of XIAP and autophagy induces apoptosis and differentiation in acute myeloid leukaemia

57 views | Jul 03 2023

In acute myeloid leukemia (AML), the inhibition of X-linked inhibitor of apoptosis (XIAP) induces autophagy, apoptosis, and differentiation, and combining XIAP inhibition with autophagy inhibition shows promise as a therapeutic strategy for AML. [Read the Full Post]

Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway

100 views | Jul 03 2023

The study suggests that combining MDM2 inhibitors with proteasome inhibitors could improve the efficacy of treatment for liposarcoma by inducing apoptosis through activation of the ATF4/CHOP stress response axis. [Read the Full Post]

Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease

24 views | Jul 03 2023

PS18, a peptide derived from prosaposin, exhibits neuroprotective effects by reducing dopaminergic neuronal loss, apoptosis, and endoplasmic reticulum stress in cellular and animal models of Parkinson's disease. [Read the Full Post]

Differential regulation of histamine H1 receptor-mediated ERK phosphorylation by Gq proteins and arrestins

92 views | Jul 02 2023

The study revealed that H1 receptor-mediated ERK phosphorylation is differentially regulated by Gq protein/Ca2+/PKC and GRK/arrestin/clathrin/Raf/MEK pathways, potentially determining the early and late phases of histamine-induced allergic and inflammatory responses. [Read the Full Post]

AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer

63 views | Jul 02 2023

The study demonstrates that the AXL inhibitor TP-0903 exhibits anti-metastatic, antitumor effects, and sensitizes pancreatic ductal adenocarcinoma to therapy, potentially providing a new treatment strategy for pancreatic cancer. [Read the Full Post]

Repurposing Axl Kinase Inhibitors for the Treatment of Respiratory Syncytial Virus Infection

38 views | Jul 02 2023

In this study, Axl kinase inhibitors demonstrated efficacy in reducing RSV infection, ameliorating pulmonary pathology, and promoting the expression of interferon-stimulated genes, suggesting their potential as broad-spectrum antiviral therapeutics. [Read the Full Post]

Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis

76 views | Jul 02 2023

Pelabresib (CPI-0610), an investigational BET inhibitor, shows promising potential as a novel treatment approach for myelofibrosis, based on preclinical and clinical data demonstrating its ability to target key oncogenic signaling pathways and provide favorable responses in symptom control and disease-related parameters. [Read the Full Post]

A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma

16 views | Jul 02 2023

The first-in-human phase I study of pelabresib demonstrated its safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity, establishing a maximum tolerated dose of 225 mg once daily and supporting its potential as a therapeutic agent for relapsed/refractory lymphomas. [Read the Full Post]

Itacitinib Population Pharmacokinetics and Exposure-Response in Patients With Acute Graft-Versus-Host Disease

56 views | Jul 01 2023

This article presents a population pharmacokinetic analysis and exposure-response assessment of itacitinib for the treatment of acute graft-versus-host disease, revealing significant predictors of treatment response and recommending dose reductions when co-administered with strong CYP3A inhibitors. [Read the Full Post]

PRMT6-CDC20 facilitates glioblastoma progression via the degradation of CDKN1B

43 views | Jul 01 2023

PRMT6, an overexpressed arginine methyltransferase in glioma/GBM, promotes cell proliferation and progression by destabilizing CDKN1B through CDC20-mediated degradation, suggesting potential therapeutic targeting of the PRMT6-CDC20-CDKN1B axis in GBM. [Read the Full Post]

Generation of a Live Attenuated Influenza A Vaccine Using Chemical-Triggered Intein

76 views | Jul 01 2023

A novel method using 4-hydroxytamoxifen (4-HT)-dependent intein insertion into the polymerase acidic (PA) protein of influenza A virus generates recombinant viruses that demonstrate excellent replication characteristics and induce robust immunity, offering potential for the development of a more effective live attenuated influenza vaccine and possibly vaccines against other pathogens as well. [Read the Full Post]

5-Oxoproline Enhances 4-Hydroxytamoxifen-induced Cytotoxicity by Increasing Oxidative Stress in MCF-7 Breast Cancer Cells

0 views | Jul 01 2023

In conclusion, the study demonstrates that 5-oxoproline enhances the cytotoxic effects of 4-hydroxytamoxifen in estrogen receptor-positive breast cancer cells under normal glucose conditions, suggesting the potential utility of monocarboxylate transporter inhibitors as adjunctive therapeutic agents. [Read the Full Post]

Downregulation of BASP1 promotes temozolomide resistance in gliomas via epigenetic activation of the FBXO32/NF-κB/MGMT axis

34 views | Jul 01 2023

Downregulation of BASP1 in gliomas leads to enhanced resistance to TMZ therapy through activation of the FBXO32/NF-κB/MGMT axis via epigenetic modifications mediated by the WDR5/MLL complex, suggesting a potential therapeutic target for combating TMZ-resistant gliomas. [Read the Full Post]

GSK484, an inhibitor of peptidyl arginine deiminase 4, increases the radiosensitivity of colorectal cancer and inhibits neutrophil extracellular traps

50 views | Jun 30 2023

The study demonstrates that the PAD4 inhibitor GSK484 enhances the radiosensitivity of colorectal cancer, induces cell death, and inhibits neutrophil extracellular trap (NET) formation, suggesting its potential as a therapeutic agent for improving treatment outcomes in CRC. [Read the Full Post]

The role of EZH2 as a potential therapeutic target in retinoblastoma

95 views | Jun 30 2023

The study reveals that the high expression of EZH2 in retinoblastoma tissues is associated with poor overall survival, and inhibiting EZH2 with UNC1999 shows promising results in suppressing RB cell proliferation, metastasis, and tumor glycolysis, making it a potential target for anti-RB treatment. [Read the Full Post]